SURROGATE BIOMARKER FOR EVALUATING INTRACEREBRAL AMYLOID PEPTIDE ACCUMULATION AND METHOD FOR ANALYSIS THEREOF

摘要

Provided are a biomarker for evaluating a cerebral A² accumulation state using an amyloid precursor protein (APP)-derived peptide in a living body-derived sample as an index, and a method for analysis thereof. A living body-derived sample derived from a test subject is measured, and at least one ratio selected from the group consisting of APP669-711/APP672-713 (A²1-42); APP672-709 (A²1-38)/APP672-713 (A²1-42); APP674-711 (A²3-40)/APP672-713 (A²1-42); APP672-710 (A²1-39)/APP672-713 (A²1-42); APP672-711 (A²1-40)/APP672-713 (A²1-42); and APP672-711 (OxA²1-40)/APP672-713 (A²1-42) is calculated, and when each of the ratios of the test subject is higher than each of standard levels which are ratios of a person having normal cognitive function NC- who is negative for cerebral A² accumulation, an accumulation amount of cerebral A² of the test subject is determined as larger than an accumulation amount of cerebral A² of the person having normal cognitive function NC-.